Company Analysis Cryo-Cell International, Inc.
1. Summary
Advantages
- Dividends (6.12%) are higher than the sector average (1.35%).
- Current debt level 20% is below 100% and has decreased over 5 years from 20.88%.
- The company's current efficiency (ROE=-3.32%) is higher than the sector average (ROE=-73.5%)
Disadvantages
- Price (4.8 $) is higher than fair price (0.3849 $)
- The stock's return over the last year (-26.15%) is lower than the sector average (-22.52%).
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
Cryo-Cell International, Inc. | Healthcare | Index | |
---|---|---|---|
7 days | -1% | -1% | 0.6% |
90 days | -7.5% | -1.7% | 8.5% |
1 year | -26.2% | -22.5% | 16.7% |
CCEL vs Sector: Cryo-Cell International, Inc. has slightly underperformed the "Healthcare" sector by -3.64% over the past year.
CCEL vs Market: Cryo-Cell International, Inc. has significantly underperformed the market by -42.9% over the past year.
Stable price: CCEL is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: CCEL with weekly volatility of -0.503% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (4.8 $) is higher than the fair price (0.3849 $).
Price is higher than fair: The current price (4.8 $) is 92% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (181.16) is higher than that of the sector as a whole (27.88).
P/E vs Market: The company's P/E (181.16) is higher than that of the market as a whole (51.17).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (-5.51) is lower than that of the sector as a whole (10.49).
P/BV vs Market: The company's P/BV (-5.51) is lower than that of the market as a whole (18.07).
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.28) is lower than that of the sector as a whole (4.13).
P/S vs Market: The company's P/S indicator (2.28) is lower than that of the market as a whole (27.88).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (59.89) is higher than that of the sector as a whole (18.07).
EV/Ebitda vs Market: The company's EV/Ebitda (59.89) is higher than that of the market as a whole (36.67).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -17.77% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-17.77%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0.1902%).
5.4. ROE
ROE vs Sector: The company's ROE (-3.32%) is higher than that of the sector as a whole (-73.5%).
ROE vs Market: The company's ROE (-3.32%) is lower than that of the market as a whole (34.36%).
5.5. ROA
ROA vs Sector: The company's ROA (0.6388%) is lower than that of the sector as a whole (6.82%).
ROA vs Market: The company's ROA (0.6388%) is lower than that of the market as a whole (11.31%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (21.56%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.96%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 6.12% is higher than the average for the sector '1.35%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 6.12% has been steadily paid over the past 7 years, DSI=0.83.
Weak dividend growth: The company's dividend yield 6.12% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (502.5%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription